Compare Alcon AG (ALC) vs Viatris Inc (VTRS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Viatris Inc — how do they compare? Alcon AG trades at $66.89 (market cap $32.69B), while Viatris Inc trades at $16.5 (market cap $19.75B). The key difference: Alcon AG is the larger of the two by market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| ALC | VTRS | |
|---|---|---|
Market Cap | $32.69B | $19.75B |
Sector | Health | Health |
52-Week High | $92.22 | $17.39 |
52-Week Low | $62.02 | $8.74 |
Enterprise Value | $36.28B | $31.96B |
Dividend Yield | 0.54% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Viatris (VTRS) trades at $16.96, up 1.56% on the day and near its 52-week high of $17.53. The stock shows a bullish technical trend with consistent earnings beats in recent quarters. However, fundamentals reveal challenges, including a net loss of $3.51 billion in 2025 and negative profit margins, though revenue remains stable around $14.3 billion. Positive developments include a strong pipeline, with recent FDA acceptance of a new drug application for fast-acting meloxicam and positive Phase 3 results for VR-205.
The outlook is mixed; analyst consensus is a 'Hold' with a $20 price target, suggesting modest upside. Key opportunities lie in pipeline catalysts and debt reduction, but risks include persistent profitability issues, high debt levels, and competitive pressures. The stock's valuation metrics like P/S of 1.35 may appeal to value investors, but earnings sustainability is a concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
